hit counter
Beyond Air, Inc. (XAIR) Stock News Sentiment & Price - Sentifly
XAIR - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Beyond Air, Inc. (XAIR)

USA
Medical Appliances & Equipment
NASDAQ
XAIR Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
XAIR Latest news
Seeking Alpha
Neutral
Beyond Air, Inc.'s (XAIR) CEO Steve Lisi on Q2 2022 Results - Earnings Call Transcript
2021-11-11 20:49

Beyond Air, Inc.'s (XAIR) CEO Steve Lisi on Q2 2022 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022
2021-11-11 16:05

U.S. FDA actively reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Remain on track for commercial launch in the fourth quarter of calendar year 2021

Zacks Investment Research
Negative
Beyond Air, Inc. (XAIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2021-11-04 16:47

Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire
Neutral
Beyond Air® to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
2021-11-02 08:00

GARDEN CITY, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 30 – December 2, 2021. Beyond Air will provide a pre-recorded investor presentation and will be available for virtual one-on-one meetings during the conference.

GlobeNewsWire
Neutral
Beyond Air® Schedules Second Fiscal Quarter 2022 Financial Results Conference Call and Webcast
2021-10-25 08:00

Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time Call scheduled for Thursday, November 11th at 4:30 pm Eastern Time

Benzinga
Neutral
Beyond Air Reports Interim Data Of Self-Administered Inhaled NO For Lung Disease
2021-10-20 10:23

Beyond Air Inc (NASDAQ: XAIR) has announced interim data from Australia's ongoing LungFit GO pilot study.  Related:   Beyond Air Issues Regulatory Update For LungFit PH System.

Benzinga
Positive
Beyond Air Issues Regulatory Update For LungFit PH System
2021-09-22 07:17

Beyond Air Inc (NASDAQ: XAIR) announced a regulatory update for the approval process of its LungFit PH system. The Company said that the FDA facility inspections are currently ongoing.

GlobeNewsWire
Neutral
Beyond Air® Provides Global Regulatory Update for LungFit® PH
2021-09-21 16:30

FDA inspection of facilities is ongoing; US commercial launch remains on track for 4Q CY2021, pending FDA approval

GlobeNewsWire
Neutral
Beyond Air® to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
2021-09-14 07:30

GARDEN CITY, N.Y., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, is scheduled to present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually from September 20th to 23rd.

GlobeNewsWire
Neutral
Beyond Air® Announces CFO Transition
2021-08-20 16:15

GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the appointment of Douglas Larson as Chief Financial Officer, succeeding Douglas Beck effective September 1, 2021. Mr. Beck will remain a consultant to the Company and is expected to work closely with Mr. Larson and the Beyond Air leadership team to ensure a seamless transition of CFO responsibilities.

Loading more news...